B
Bull
Bull · 25%ELEV
$0.47
情景价格
$0.365
-0.008 (-2.12%)收盘时
Loading chart…
- High
- 0.379
- Open
- 0.374
- VWAP
- 0.37
- Vol
- 4.82M
- Mkt Cap
- 137.14M
- Low
- 0.353
- Amount
- 1.76M
- EV/EBITDA, TTM
- 0.00
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
估值指标
The current forward P/E ratio for Elevation Oncology Inc (ELEV) is -0.61, compared to its 5-year average forward P/E of -1.48.
Alphio AI Price Scenarios for ELEV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
5.001-08GlobenewswireEleva Appoints New CBO Erich Rajkovic to Drive Strategic Expansion
7.006-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders
8.506-15GlobenewswireHAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
7.006-13GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders
7.006-13GlobenewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)
ELEV FAQ — answered by Alphio AI
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。